The accumulation of amyloid-beta protein plaques in the cerebral cortex is a hallmark of Alzheimer's disease (AD). Amyloid-beta is produced by the proteolytic cleavage of amyloid precursor protein (APP), which is mediated by the enzymes beta- and gamma-secretase. This cleavage reaction produces a number of peptides ranging from 36 to 43 amino acids in length. Our antibodies and ELISA kits detect a variety of human amyloid-beta variants and oligomers.
ELISAs for Human Amyloid-Beta Detection
Amyloid-beta insoluble protein is the main component of plaques found in the brains of patients with AD; however, recent research suggests that soluble, oligomeric forms of Amyloid-Beta are also involved in this disease. The amyloid-beta kits are solid-phase sandwich ELISAs that use two highly specific antibodies—one is precoated onto the ELISA plate and the other is HRP-conjugated.
Antibodies for Human Amyloid-Beta Detection
These products are affinity-purified IgG antibodies that recognize human amyloid-beta variants cleaved at the N-terminus or C-terminus. Our human amyloid-beta antibodies are raised in mice (Human Amyloid-beta Antibodies, Cat. #10027, 10323, 10326 & 10379) and in rabbits (Anti-Human Amyloid-beta Rabbit IgG Antibody, Cat. #18584) using a synthetic peptide. These antibodies are suitable for Western blot (WB) detection, immunohistochemical (IHC) detection, and immunoprecipitation (IP).